NFKB1 and Alzheimer disease: The activation of NF-κB has been observed in the brains of AD patients, and disrupting the NF-κB pathway decreases β-site APP-cleaving enzyme 1 expression and Aβ generation, leading to memory deficits and reduced neurogenesis in vivo88–90.